Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TrivarX Limited ( (AU:TRI) ) has provided an announcement.
TrivarX Limited has announced positive interim results from its clinical trial in collaboration with the Greater Los Angeles Research and Education Foundation and US Veterans Affairs Greater Los Angeles Healthcare System. The trial evaluates the company’s single-lead ECG algorithm for screening major depressive episodes in veterans. The interim results show strong sensitivity and specificity, reinforcing the potential clinical utility of TrivarX’s technology. The company is focused on completing patient recruitment and exploring commercial opportunities for its technology.
More about TrivarX Limited
TrivarX Limited is a mental health technology company that focuses on using objective measures to aid in the early detection and screening of mental health conditions. Founded in Australia, the company has offices in Perth and Minneapolis and is listed on the Australian Securities Exchange and the OTCQB Venture Market.
YTD Price Performance: -31.25%
Average Trading Volume: 1,390,315
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.82M
See more data about TRI stock on TipRanks’ Stock Analysis page.